Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: A case report

Shalhoub, Sarah; Alzahrani, Abdulwahab B.; Simhairi, Raed; Mushtaq, Adnan

doi:10.1016/j.jcv.2014.11.030

Cited by 26 publications

(34 citation statements)

References 11 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 1095 references were retrieved. Upon screening them regarding inclusion and exclusion criteria from Section 2, eleven references were included for data extraction and analysis . Additionally, 5 references were identified through manual search .…”

Section: Resultsmentioning

confidence: 99%

“…Of the 16 studies including 116 patients, 10 were case reports, 2 were case series, and 4 were observational studies . Saudi Arabia was the country of origin for patients in 13 studies, and the rest were from France, Greece, and Qatar.…”

Section: Resultsmentioning

confidence: 99%

“…Eight studies used specific antiviral treatment while 7 studies used supportive treatment (including invasive ventilation, prone position, renal replacement therapy, vasopressors, corticosteroids, immunoglobulins, and oseltamivir) . Omrani et al used both specific antiviral treatment and supportive treatment.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis

Morra

Kamel

et al. 2018

Reviews in Medical Virology

160

146

View full text Add to dashboard Cite

Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus. Because of lack of vaccination, various studies investigated the therapeutic efficacy of antiviral drugs and supportive remedies. A systematic literature search from 10 databases was conducted and screened for relevant articles. Studies reporting information about the treatment of MERS coronavirus infection were extracted and analyzed. Despite receiving treatment with ribavirin plus IFN, the case fatality rate was as high as 71% in the IFN-treatment group and exactly the same in patients who received supportive treatment only. Having chronic renal disease, diabetes mellitus and hypertension increased the risk of mortality (P < .05), and chronic renal disease is the best parameter to predict the mortality. The mean of survival days from onset of illness to death was 46.6 (95% CI, 30.5-62.6) for the IFN group compared with 18.8 (95% CI, 10.3-27.4) for the supportive-only group (P = .001). Delay in starting treatment, older age group, and preexisting comorbidities are associated with worse outcomes. In conclusion, there is no difference between IFN treatment and supportive treatment for MERS patients in terms of mortality. However, ribavirin and IFN combination might have efficacious effects with timely administration and monitoring of adverse events. Large-scale prospective randomized studies are required to assess the role of antiviral drugs for the treatment of this high mortality infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis

Morra

Kamel

et al. 2018

Reviews in Medical Virology

160

146

View full text Add to dashboard Cite

show abstract

“…The clinical course is more severe in immunocompromised patients (6), (although recent case reports indicate that some recover) (45,46), and in pregnant women, where infection has been shown to result in stillbirths. The clinical course is more likely to be mild in individuals without underlying medical conditions (7,(47)(48)(49).…”

Section: Clinical Characteristicsmentioning

confidence: 99%

Middle East respiratory syndrome coronavirus: current knowledge and future considerations

Malik¹,

Elkholy²,

Khan³

et al. 2016

East Mediterr Health J

View full text Add to dashboard Cite

A literature review of publically available information was undertaken to summarize current understanding and gaps in knowledge about Middle East respiratory syndrome coronavirus (MERS-CoV), including its origin, transmission, effective control measures and management. Major databases were searched and relevant published papers and reports during 2012-2015 were reviewed. Of the 2520 publications initially retrieved, 164 were deemed relevant. The collected results suggest that much remains to be discovered about MERS-CoV. Improved surveillance, epidemiological research and development of new therapies and vaccines are important, and the momentum of recent gains in terms of better understanding of disease patterns should be maintained to enable the global community to answer the remaining questions about this disease.

show abstract

“…As per the authors’ knowledge, two studies have so far addressed clinical improvement on laboratory‐confirmed MERS‐CoV patients . The first study, Shalhoub et al, was based on a case report in which their observations may not be generalized to a wider MERS‐CoV population. The second study, Al‐Turaiki et al, utilized publicly available data from the Saudi Ministry of Health.…”

Section: Introductionmentioning

confidence: 99%

Factors associated with recovery delay in a sample of patients diagnosed by MERS‐CoV rRT‐PCR: A Saudi Arabian multicenter retrospective study

Ahmed

Al‐Jahdali

Alaqeel

et al. 2018

Influenza Resp Viruses

View full text Add to dashboard Cite

BackgroundResearch evidence exists that poor prognosis is common in Middle East respiratory syndrome coronavirus (MERS‐CoV) patients.ObjectivesThis study estimates recovery delay intervals and identifies associated factors in a sample of Saudi Arabian patients admitted for suspected MERS‐CoV and diagnosed by rRT‐PCR assay.MethodsA multicenter retrospective study was conducted on 829 patients admitted between September 2012 and June 2016 and diagnosed by rRT‐PCR procedures to have MERS‐CoV and non‐MERS‐CoV infection in which 396 achieved recovery. Detailed medical charts were reviewed for each patient who achieved recovery. Time intervals in days were calculated from presentation to the initial rRT‐PCR diagnosis (diagnosis delay) and from the initial rRT‐PCR diagnosis to recovery (recovery delay).ResultsThe median recovery delay in our sample was 5 days. According to the multivariate negative binomial model, elderly (age ≥ 65), MERS‐CoV infection, ICU admission, and abnormal radiology findings were associated with longer recovery delay (adjusted relative risk (aRR): 1.741, 2.138, 2.048, and 1.473, respectively). Camel contact and the presence of respiratory symptoms at presentation were associated with a shorter recovery delay (expedited recovery) (aRR: 0.267 and 0.537, respectively). Diagnosis delay is a positive predictor for recovery delay (r = .421; P = .001).ConclusionsThe study evidence supports that longer recovery delay was seen in patients of older age, MERS‐CoV infection, ICU admission, and abnormal radiology findings. Shorter recovery delay was found in patients who had camel contact and respiratory symptoms at presentation. These findings may help us understand clinical decision making on directing hospital resources toward prompt screening, monitoring, and implementing clinical recovery and treatment strategies.

show abstract

Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: A case report

Cited by 26 publications

References 11 publications

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis

Middle East respiratory syndrome coronavirus: current knowledge and future considerations

Factors associated with recovery delay in a sample of patients diagnosed by MERS‐CoV rRT‐PCR: A Saudi Arabian multicenter retrospective study

Contact Info

Product

Resources

About